Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727463 | 0.77 | ADRA1D (0.45) | MEN1KMT2AALDH1A1KDM4EADRA1D | |
| SCHEMBL12978568 | 0.75 | ALDH1A1 (0.45) | MEN1KMT2AALDH1A1KDM4ENPC1 | |
| SCHEMBL3319870 | 0.74 | MEN1 (0.43) | MEN1KMT2AALDH1A1KDM4ESIRT2 | |
| SCHEMBL3705964 | 0.74 | IDO1 (0.36) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1318759 | 0.71 | TSHR (0.52) | MEN1KMT2AALDH1A1KDM4EADRA1D | |
| SCHEMBL1927794 | 0.69 | HDAC8 (0.57) | MEN1KMT2AHDAC3NCOR2 | |
| SCHEMBL27630839 | 0.69 | IDO1 (0.45) | LMNA | |
| SCHEMBL15775328 | 0.68 | L3MBTL1 (0.41) | MEN1KMT2AALDH1A1KDM4EADRA1D | |
| Benzene SCHEMBL28276192 | 0.68 | KDM4E (0.46) | MEN1KMT2AALDH1A1KDM4EADRA1D | |
| SCHEMBL1004028 | 0.67 | TSHR (0.58) | MEN1KMT2AALDH1A1KDM4EADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513432-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120238611-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8212052-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2225210-A1 | DUAL-ACTING BENZOIMIDAZOLE DERIVATIVE AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009076288-A1 | DUAL-ACTING BENZOIMIDAZOLE DERIVATIVE AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238611-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MEN1 2934/4885KMT2A 2262/4885ALDH1A1 2053/4885 |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MEN1 2934/4885KMT2A 2262/4885ALDH1A1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.